PDCD1 and non-small cell lung carcinoma: While we cannot rule out a beneficial effect of the combination in all tumors with immune refractory TMEs, as our models certainly do not cover the whole spectrum of immunogenicity observed in NSCLC patients, it will be of utmost importance to identify which patients can benefit from the addition of anti-PD1 inhibitors to KRASG12C inhibitors and to investigate additional therapeutic strategies for the remaining patients.